Shionogi & Co 4507.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4507.T. It has been listed since 16 May 1949. In the fiscal year to 31 March 2026, it reported revenue of ¥499.68bn and net income of ¥205.16bn. At that date it held total assets of ¥2.58trn and shareholders' equity of ¥1.69trn.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. The company is headquartered in Osaka, Osaka-Fu. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The firm is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The firm mainly provides its products and services in Japan, Europe and North America markets.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Isao TeshirogiChairman of the Board, President, Chief Executive Officer, Representative Director, since 2007¥272.0m
• Ms. Takuko SawadaVice Chairman of the Board, since 2011¥157.0m
• Mr. Koji HanasakiSenior Executive Officer
• Mr. Kazuhiro HatanakaSenior Executive Officer, Chief Director of Corporate Strategy
• Mr. Yasuyoshi IsouSenior Executive Officer, Chief Director of Drug Discovery Research
• Mr. Toshinobu IwasakiSenior Executive Officer
• Mr. Akira KatoSenior Executive Officer, President of Subsidiary
• Mr. John KellerSenior Executive Officer
• Mr. Ryuichi KiyamaSenior Executive Officer, Chief Director of Management Support
• Mr. Yasunori AoyamaExecutive Officer, Chief Director of Pharmaceutical Technology Research
• Mr. Masashi DeguchiExecutive Officer, Chief Director of DX Promotion
• Mr. Yousuke MiharuExecutive Officer, Chief Director of Healthcare Strategy

Overall

92

Environment

99

Social

99

Governance

79

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.